Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities
Net loss	$ (1,052)	$ (1,980)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities
Gain on sale of in-process research and development	(445)	(144)
Stock-based compensation expense	54	354
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(57)	1,870
Accounts payable, accrued expenses and other	(114)	(87)
Other assets	57	124
Net cash (used in) provided by operating activities	(1,557)	137
Cash flows from investing activities
Net proceeds from sale of in process research and development	445	144
Net cash provided by investing activities	445	144
Cash flows from financing activities
Proceeds from exercise of stock options		239
Net cash provided by financing activities		239
Net (decrease) increase in cash and cash equivalents	(1,112)	520
Cash and cash equivalents, beginning of period	14,203	14,038
Cash and cash equivalents, end of period	$ 13,091	$ 14,558